News

The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.

Exenatide shows effects on brain metabolism in Parkinson disease but fails to provide clinical benefits, as recent trials reveal mixed results.

The professor of clinical neuroscience at Newcastle University discussed selecting appropriate and representative patient populations across different phases of clinical trials for Parkinson disease. [WATCH TIME: 5 minutes]

The assistant professor of neurology at Northwestern University shared important clinical insights for early-career clinicians entering neuroimmunology, emphasizing best practices in recognizing, testing, and confirming NMOSD. [WATCH TIME: 3 minutes]

Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure during pregnancy and lactation in women with MS.

Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.

Here's some of what is coming soon to NeurologyLive® this week.

In a recent study of patients with testicular germ cell tumors, most exhibited paraneoplastic neurologic syndromes proceeding with their cancer diagnosis, often associated with specific neural autoantibodies.

In this final episode, Drs. Snelling and De Los Rios share lessons from building a coordinated, multi-hospital stroke system and how network integration improves speed, access, and outcomes. [WATCH TIME: 3 minutes]

A recent study highlights the increased mortality risk linked to benzodiazepine and antipsychotic use in hospice patients with dementia, urging new prescribing guidelines.

Neurology News Network for the week ending October 25, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 24, 2025.

In episode 4, neurologists Brian Snelling, MD, and Felipe De Los Rios, MD, discuss how stroke recovery and secondary prevention have evolved, highlighting new therapies, combination strategies, and the complexities of real-world implementation. [WATCH TIME: 4 minutes]

A recent meta-analysis reveals frontotemporal dementia's incidence and prevalence, highlighting its significance in clinical research and treatment advancements.

At CNS 2025, the associate professor of neurology and pediatrics at the University of Virginia discussed using educational model frameworks to prepare child neurology trainees for clinical practice. [WATCH TIME: 3 minutes]

In a recent randomized clinical trial, a smartphone-based relaxation technique provided to patients presenting to the emergency department was associated with reduced migraine-related disability.

The FDA has granted fast track designation to Eisai’s etalanetug, an anti-tau antibody targeting tau pathology in Alzheimer's disease.

The conversation centers around the pursuit of effective neuroprotective agents in stroke, the challenges of clinical trial design, and what could make future therapies succeed. [WATCH TIME: 5 minutes]

James N. Brenton, MD, director of the Pediatric MS and Related Disorders Clinic at the University of Virginia, discussed how lifestyle modification and multidisciplinary care can support disease management in children with multiple sclerosis.

At CNS 2025, the program director of child neurology residency at Boston Children's Hospital discussed strategies to expose medical students to child neurology early in their clinical training. [WATCH TIME: 4 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.

In episode 2, a pair of stroke neurologists explore how artificial intelligence is accelerating stroke detection, streamlining workflows, and redefining collaboration in modern stroke care. [WATCH TIME: 4 minutes]

New findings reveal early treatment with Trappsol Cyclo shows promise for young patients with Niemann-Pick disease type C1, enhancing safety and efficacy.

The president and founder of the Stuttering Treatment and Research Society highlighted the significance of interdisciplinary care for both children and adults with stuttering. [WATCH TIME: 5 minutes]

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

David Stamler, MD, CEO at Alterity Therapeutics, gave clinical perspectives on ATH434, an emerging agent showing promise in phase 2 studies of multiple system atrophy.